U.S. markets closed
  • S&P 500

    4,232.60
    +30.98 (+0.74%)
     
  • Dow 30

    34,777.76
    +229.23 (+0.66%)
     
  • Nasdaq

    13,752.24
    +119.39 (+0.88%)
     
  • Russell 2000

    2,271.63
    +30.21 (+1.35%)
     
  • Crude Oil

    64.82
    +0.11 (+0.17%)
     
  • Gold

    1,832.00
    +16.30 (+0.90%)
     
  • Silver

    27.57
    +0.09 (+0.32%)
     
  • EUR/USD

    1.2167
    +0.0098 (+0.82%)
     
  • 10-Yr Bond

    1.5770
    +0.0160 (+1.02%)
     
  • GBP/USD

    1.3990
    +0.0098 (+0.70%)
     
  • USD/JPY

    108.5400
    -0.5450 (-0.50%)
     
  • BTC-USD

    58,480.48
    +684.49 (+1.18%)
     
  • CMC Crypto 200

    1,480.07
    +44.28 (+3.08%)
     
  • FTSE 100

    7,129.71
    +53.54 (+0.76%)
     
  • Nikkei 225

    29,357.82
    +26.45 (+0.09%)
     

Mersana Therapeutics Starts UpRi Dosing In Heavily Pretreated Cohort Of Ovarian Cancer Patients

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Mersana Therapeutics Inc (NASDAQ: MRSN) has initiated patient dosing in the UPLIFT study evaluating upifitamab rilsodotin in patients with ovarian cancer.

  • The single-arm registration strategy will evaluate the safety and efficacy of upifitamab rilsodotin in platinum-resistant ovarian cancer patients who have received up to four lines of therapy.

  • The primary endpoint will be the objective response rate (ORR) in the high NaPi2b population. The secondary endpoints will be the ORR regardless of NaPi2b expression and response and safety duration.

  • The Company expects to enroll approximately 100 patients with high NaPi2b expression and up to 180 patients overall.

  • This study's design is an amendment to the ongoing Phase 1 expansion study that thoroughly evaluates the biomarker's role with endpoints in both the high NaPi2b and overall populations.

  • Price Action: MRSN shares are down 0.56% at $16.01 during market trading hours on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.